CN115317429B - 含重组胶原蛋白具有修护舒缓功效的组合物、含有该组合物的眼霜及制备方法和应用 - Google Patents
含重组胶原蛋白具有修护舒缓功效的组合物、含有该组合物的眼霜及制备方法和应用 Download PDFInfo
- Publication number
- CN115317429B CN115317429B CN202211058014.XA CN202211058014A CN115317429B CN 115317429 B CN115317429 B CN 115317429B CN 202211058014 A CN202211058014 A CN 202211058014A CN 115317429 B CN115317429 B CN 115317429B
- Authority
- CN
- China
- Prior art keywords
- parts
- mixture
- composition
- skin
- repairing
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 111
- 230000000694 effects Effects 0.000 title claims abstract description 52
- 102000008186 Collagen Human genes 0.000 title claims abstract description 37
- 108010035532 Collagen Proteins 0.000 title claims abstract description 37
- 229920001436 collagen Polymers 0.000 title claims abstract description 37
- 239000006071 cream Substances 0.000 title claims abstract description 35
- 238000002360 preparation method Methods 0.000 title claims abstract description 31
- WTVHAMTYZJGJLJ-UHFFFAOYSA-N (+)-(4S,8R)-8-epi-beta-bisabolol Natural products CC(C)=CCCC(C)C1(O)CCC(C)=CC1 WTVHAMTYZJGJLJ-UHFFFAOYSA-N 0.000 claims abstract description 15
- RGZSQWQPBWRIAQ-CABCVRRESA-N (-)-alpha-Bisabolol Chemical compound CC(C)=CCC[C@](C)(O)[C@H]1CCC(C)=CC1 RGZSQWQPBWRIAQ-CABCVRRESA-N 0.000 claims abstract description 15
- 240000004808 Saccharomyces cerevisiae Species 0.000 claims abstract description 15
- RGZSQWQPBWRIAQ-LSDHHAIUSA-N alpha-Bisabolol Natural products CC(C)=CCC[C@@](C)(O)[C@@H]1CCC(C)=CC1 RGZSQWQPBWRIAQ-LSDHHAIUSA-N 0.000 claims abstract description 15
- HHGZABIIYIWLGA-UHFFFAOYSA-N bisabolol Natural products CC1CCC(C(C)(O)CCC=C(C)C)CC1 HHGZABIIYIWLGA-UHFFFAOYSA-N 0.000 claims abstract description 15
- 229940036350 bisabolol Drugs 0.000 claims abstract description 15
- 238000000855 fermentation Methods 0.000 claims abstract description 14
- 230000004151 fermentation Effects 0.000 claims abstract description 14
- 239000006166 lysate Substances 0.000 claims abstract description 14
- 239000011550 stock solution Substances 0.000 claims abstract description 12
- 150000001875 compounds Chemical class 0.000 claims abstract description 10
- 229920002385 Sodium hyaluronate Polymers 0.000 claims abstract description 9
- 229940010747 sodium hyaluronate Drugs 0.000 claims abstract description 9
- YWIVKILSMZOHHF-QJZPQSOGSA-N sodium;(2s,3s,4s,5r,6r)-6-[(2s,3r,4r,5s,6r)-3-acetamido-2-[(2s,3s,4r,5r,6r)-6-[(2r,3r,4r,5s,6r)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2- Chemical compound [Na+].CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 YWIVKILSMZOHHF-QJZPQSOGSA-N 0.000 claims abstract description 9
- 238000003756 stirring Methods 0.000 claims description 26
- 238000002156 mixing Methods 0.000 claims description 23
- 239000000284 extract Substances 0.000 claims description 21
- 239000002994 raw material Substances 0.000 claims description 21
- 238000001816 cooling Methods 0.000 claims description 20
- 240000007817 Olea europaea Species 0.000 claims description 16
- 229940049964 oleate Drugs 0.000 claims description 16
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 claims description 16
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 16
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 14
- 235000014680 Saccharomyces cerevisiae Nutrition 0.000 claims description 14
- 238000010438 heat treatment Methods 0.000 claims description 14
- 238000000034 method Methods 0.000 claims description 12
- 229940100515 sorbitan Drugs 0.000 claims description 11
- -1 cetyl stearyl Chemical group 0.000 claims description 10
- 239000008367 deionised water Substances 0.000 claims description 10
- 229910021641 deionized water Inorganic materials 0.000 claims description 10
- 239000003995 emulsifying agent Substances 0.000 claims description 9
- CDQSJQSWAWPGKG-UHFFFAOYSA-N butane-1,1-diol Chemical compound CCCC(O)O CDQSJQSWAWPGKG-UHFFFAOYSA-N 0.000 claims description 8
- 239000003755 preservative agent Substances 0.000 claims description 8
- 230000002335 preservative effect Effects 0.000 claims description 8
- 239000002562 thickening agent Substances 0.000 claims description 8
- 239000003963 antioxidant agent Substances 0.000 claims description 7
- 230000003078 antioxidant effect Effects 0.000 claims description 7
- 235000006708 antioxidants Nutrition 0.000 claims description 7
- FLPJVCMIKUWSDR-UHFFFAOYSA-N 2-(4-formylphenoxy)acetamide Chemical compound NC(=O)COC1=CC=C(C=O)C=C1 FLPJVCMIKUWSDR-UHFFFAOYSA-N 0.000 claims description 6
- TXFPEBPIARQUIG-UHFFFAOYSA-N 4'-hydroxyacetophenone Chemical compound CC(=O)C1=CC=C(O)C=C1 TXFPEBPIARQUIG-UHFFFAOYSA-N 0.000 claims description 6
- 235000008331 Pinus X rigitaeda Nutrition 0.000 claims description 6
- 235000011613 Pinus brutia Nutrition 0.000 claims description 6
- 241000018646 Pinus brutia Species 0.000 claims description 6
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 claims description 6
- 229940074979 cetyl palmitate Drugs 0.000 claims description 6
- 239000002738 chelating agent Substances 0.000 claims description 6
- 239000003974 emollient agent Substances 0.000 claims description 6
- PXDJXZJSCPSGGI-UHFFFAOYSA-N hexadecanoic acid hexadecyl ester Natural products CCCCCCCCCCCCCCCCOC(=O)CCCCCCCCCCCCCCC PXDJXZJSCPSGGI-UHFFFAOYSA-N 0.000 claims description 6
- 229910021645 metal ion Inorganic materials 0.000 claims description 6
- QCDWFXQBSFUVSP-UHFFFAOYSA-N 2-phenoxyethanol Chemical compound OCCOC1=CC=CC=C1 QCDWFXQBSFUVSP-UHFFFAOYSA-N 0.000 claims description 5
- 238000007599 discharging Methods 0.000 claims description 5
- 229960005150 glycerol Drugs 0.000 claims description 5
- 239000003906 humectant Substances 0.000 claims description 5
- 229960005323 phenoxyethanol Drugs 0.000 claims description 5
- 229920005862 polyol Polymers 0.000 claims description 5
- 150000003077 polyols Chemical class 0.000 claims description 5
- DTGKSKDOIYIVQL-WEDXCCLWSA-N (+)-borneol Chemical compound C1C[C@@]2(C)[C@@H](O)C[C@@H]1C2(C)C DTGKSKDOIYIVQL-WEDXCCLWSA-N 0.000 claims description 4
- 229940015975 1,2-hexanediol Drugs 0.000 claims description 4
- BANXPJUEBPWEOT-UHFFFAOYSA-N 2-methyl-Pentadecane Chemical compound CCCCCCCCCCCCCC(C)C BANXPJUEBPWEOT-UHFFFAOYSA-N 0.000 claims description 4
- 206010004542 Bezoar Diseases 0.000 claims description 4
- FHKSXSQHXQEMOK-UHFFFAOYSA-N hexane-1,2-diol Chemical compound CCCCC(O)CO FHKSXSQHXQEMOK-UHFFFAOYSA-N 0.000 claims description 4
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 claims description 4
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 claims description 4
- OULAJFUGPPVRBK-UHFFFAOYSA-N tetratriacontan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCO OULAJFUGPPVRBK-UHFFFAOYSA-N 0.000 claims description 4
- OMIGHNLMNHATMP-UHFFFAOYSA-N 2-hydroxyethyl prop-2-enoate Chemical compound OCCOC(=O)C=C OMIGHNLMNHATMP-UHFFFAOYSA-N 0.000 claims description 3
- ANZUDYZHSVGBRF-UHFFFAOYSA-N 3-ethylnonane-1,2,3-triol Chemical compound CCCCCCC(O)(CC)C(O)CO ANZUDYZHSVGBRF-UHFFFAOYSA-N 0.000 claims description 3
- 241000563984 Ampelopsis Species 0.000 claims description 3
- 235000009388 Parthenocissus quinquefolia Nutrition 0.000 claims description 3
- 241001558929 Sclerotium <basidiomycota> Species 0.000 claims description 3
- 239000002671 adjuvant Substances 0.000 claims description 3
- 229920001577 copolymer Polymers 0.000 claims description 3
- 239000004205 dimethyl polysiloxane Substances 0.000 claims description 3
- 229920000435 poly(dimethylsiloxane) Polymers 0.000 claims description 3
- 150000005846 sugar alcohols Polymers 0.000 claims description 3
- XDOFQFKRPWOURC-UHFFFAOYSA-N 16-methylheptadecanoic acid Chemical compound CC(C)CCCCCCCCCCCCCCC(O)=O XDOFQFKRPWOURC-UHFFFAOYSA-N 0.000 claims description 2
- 229940043268 2,2,4,4,6,8,8-heptamethylnonane Drugs 0.000 claims description 2
- SPSPIUSUWPLVKD-UHFFFAOYSA-N 2,3-dibutyl-6-methylphenol Chemical compound CCCCC1=CC=C(C)C(O)=C1CCCC SPSPIUSUWPLVKD-UHFFFAOYSA-N 0.000 claims description 2
- UIVPNOBLHXUKDX-UHFFFAOYSA-N 3,5,5-trimethylhexyl 3,5,5-trimethylhexanoate Chemical compound CC(C)(C)CC(C)CCOC(=O)CC(C)CC(C)(C)C UIVPNOBLHXUKDX-UHFFFAOYSA-N 0.000 claims description 2
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 claims description 2
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 claims description 2
- 239000003109 Disodium ethylene diamine tetraacetate Substances 0.000 claims description 2
- ZGTMUACCHSMWAC-UHFFFAOYSA-L EDTA disodium salt (anhydrous) Chemical compound [Na+].[Na+].OC(=O)CN(CC([O-])=O)CCN(CC(O)=O)CC([O-])=O ZGTMUACCHSMWAC-UHFFFAOYSA-L 0.000 claims description 2
- 241001619461 Poria <basidiomycete fungus> Species 0.000 claims description 2
- FSEJJKIPRNUIFL-UHFFFAOYSA-N [2,2-bis(hydroxymethyl)-3-octadecanoyloxypropyl] octadecanoate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(CO)(CO)COC(=O)CCCCCCCCCCCCCCCCC FSEJJKIPRNUIFL-UHFFFAOYSA-N 0.000 claims description 2
- 235000013871 bee wax Nutrition 0.000 claims description 2
- 239000012166 beeswax Substances 0.000 claims description 2
- CZBZUDVBLSSABA-UHFFFAOYSA-N butylated hydroxyanisole Chemical compound COC1=CC=C(O)C(C(C)(C)C)=C1.COC1=CC=C(O)C=C1C(C)(C)C CZBZUDVBLSSABA-UHFFFAOYSA-N 0.000 claims description 2
- 235000010354 butylated hydroxytoluene Nutrition 0.000 claims description 2
- 229940082500 cetostearyl alcohol Drugs 0.000 claims description 2
- SOYKEARSMXGVTM-UHFFFAOYSA-N chlorphenamine Chemical compound C=1C=CC=NC=1C(CCN(C)C)C1=CC=C(Cl)C=C1 SOYKEARSMXGVTM-UHFFFAOYSA-N 0.000 claims description 2
- 229960003291 chlorphenamine Drugs 0.000 claims description 2
- 239000002131 composite material Substances 0.000 claims description 2
- SZXQTJUDPRGNJN-UHFFFAOYSA-N dipropylene glycol Chemical compound OCCCOCCCO SZXQTJUDPRGNJN-UHFFFAOYSA-N 0.000 claims description 2
- 235000019301 disodium ethylene diamine tetraacetate Nutrition 0.000 claims description 2
- LNTHITQWFMADLM-UHFFFAOYSA-N gallic acid Chemical class OC(=O)C1=CC(O)=C(O)C(O)=C1 LNTHITQWFMADLM-UHFFFAOYSA-N 0.000 claims description 2
- ACCCMOQWYVYDOT-UHFFFAOYSA-N hexane-1,1-diol Chemical compound CCCCCC(O)O ACCCMOQWYVYDOT-UHFFFAOYSA-N 0.000 claims description 2
- 229940100554 isononyl isononanoate Drugs 0.000 claims description 2
- KUVMKLCGXIYSNH-UHFFFAOYSA-N isopentadecane Natural products CCCCCCCCCCCCC(C)C KUVMKLCGXIYSNH-UHFFFAOYSA-N 0.000 claims description 2
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 claims description 2
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 claims description 2
- 229960002216 methylparaben Drugs 0.000 claims description 2
- GLDOVTGHNKAZLK-UHFFFAOYSA-N octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCO GLDOVTGHNKAZLK-UHFFFAOYSA-N 0.000 claims description 2
- UWJJYHHHVWZFEP-UHFFFAOYSA-N pentane-1,1-diol Chemical compound CCCCC(O)O UWJJYHHHVWZFEP-UHFFFAOYSA-N 0.000 claims description 2
- 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 claims description 2
- 239000004405 propyl p-hydroxybenzoate Substances 0.000 claims description 2
- 229960003415 propylparaben Drugs 0.000 claims description 2
- 239000000600 sorbitol Substances 0.000 claims description 2
- UEUXEKPTXMALOB-UHFFFAOYSA-J tetrasodium;2-[2-[bis(carboxylatomethyl)amino]ethyl-(carboxylatomethyl)amino]acetate Chemical compound [Na+].[Na+].[Na+].[Na+].[O-]C(=O)CN(CC([O-])=O)CCN(CC([O-])=O)CC([O-])=O UEUXEKPTXMALOB-UHFFFAOYSA-J 0.000 claims description 2
- 229930003799 tocopherol Natural products 0.000 claims description 2
- 239000011732 tocopherol Substances 0.000 claims description 2
- 235000019149 tocopherols Nutrition 0.000 claims description 2
- QUEDXNHFTDJVIY-UHFFFAOYSA-N γ-tocopherol Chemical class OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1 QUEDXNHFTDJVIY-UHFFFAOYSA-N 0.000 claims description 2
- WSWCOQWTEOXDQX-MQQKCMAXSA-M (E,E)-sorbate Chemical compound C\C=C\C=C\C([O-])=O WSWCOQWTEOXDQX-MQQKCMAXSA-M 0.000 claims 2
- 229940075554 sorbate Drugs 0.000 claims 2
- 244000293323 Cosmos caudatus Species 0.000 claims 1
- 235000005956 Cosmos caudatus Nutrition 0.000 claims 1
- 240000000902 Diospyros discolor Species 0.000 claims 1
- 235000003115 Diospyros discolor Nutrition 0.000 claims 1
- 229940008099 dimethicone Drugs 0.000 claims 1
- 239000003002 pH adjusting agent Substances 0.000 claims 1
- 230000007794 irritation Effects 0.000 abstract description 26
- 230000008591 skin barrier function Effects 0.000 abstract description 11
- 231100000245 skin permeability Toxicity 0.000 abstract description 7
- 201000004624 Dermatitis Diseases 0.000 abstract description 5
- 230000008901 benefit Effects 0.000 abstract description 5
- 239000000306 component Substances 0.000 description 50
- 210000003491 skin Anatomy 0.000 description 48
- 238000012360 testing method Methods 0.000 description 40
- 239000000047 product Substances 0.000 description 34
- 230000000052 comparative effect Effects 0.000 description 31
- 210000003837 chick embryo Anatomy 0.000 description 18
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 16
- 102100040247 Tumor necrosis factor Human genes 0.000 description 16
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 15
- 210000003711 chorioallantoic membrane Anatomy 0.000 description 11
- JNYAEWCLZODPBN-JGWLITMVSA-N (2r,3r,4s)-2-[(1r)-1,2-dihydroxyethyl]oxolane-3,4-diol Chemical compound OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O JNYAEWCLZODPBN-JGWLITMVSA-N 0.000 description 9
- 230000003110 anti-inflammatory effect Effects 0.000 description 9
- 235000013601 eggs Nutrition 0.000 description 8
- 230000005764 inhibitory process Effects 0.000 description 8
- 239000000126 substance Substances 0.000 description 8
- 230000000638 stimulation Effects 0.000 description 7
- 210000004027 cell Anatomy 0.000 description 6
- 230000001804 emulsifying effect Effects 0.000 description 6
- 239000003921 oil Substances 0.000 description 6
- 230000008439 repair process Effects 0.000 description 6
- 238000010998 test method Methods 0.000 description 6
- 210000004204 blood vessel Anatomy 0.000 description 5
- 239000002158 endotoxin Substances 0.000 description 5
- 229920006008 lipopolysaccharide Polymers 0.000 description 5
- 239000013642 negative control Substances 0.000 description 5
- 230000001737 promoting effect Effects 0.000 description 5
- 239000002537 cosmetic Substances 0.000 description 4
- 210000004207 dermis Anatomy 0.000 description 4
- 235000011187 glycerol Nutrition 0.000 description 4
- 239000002245 particle Substances 0.000 description 4
- REPVLJRCJUVQFA-UHFFFAOYSA-N (-)-isopinocampheol Natural products C1C(O)C(C)C2C(C)(C)C1C2 REPVLJRCJUVQFA-UHFFFAOYSA-N 0.000 description 3
- GOZMBJCYMQQACI-UHFFFAOYSA-N 6,7-dimethyl-3-[[methyl-[2-[methyl-[[1-[3-(trifluoromethyl)phenyl]indol-3-yl]methyl]amino]ethyl]amino]methyl]chromen-4-one;dihydrochloride Chemical compound Cl.Cl.C=1OC2=CC(C)=C(C)C=C2C(=O)C=1CN(C)CCN(C)CC(C1=CC=CC=C11)=CN1C1=CC=CC(C(F)(F)F)=C1 GOZMBJCYMQQACI-UHFFFAOYSA-N 0.000 description 3
- 102000002322 Egg Proteins Human genes 0.000 description 3
- 108010000912 Egg Proteins Proteins 0.000 description 3
- 206010015150 Erythema Diseases 0.000 description 3
- 206010015946 Eye irritation Diseases 0.000 description 3
- 206010061218 Inflammation Diseases 0.000 description 3
- 208000002193 Pain Diseases 0.000 description 3
- 206010034018 Parosmia Diseases 0.000 description 3
- 244000197580 Poria cocos Species 0.000 description 3
- 235000008599 Poria cocos Nutrition 0.000 description 3
- 229940116229 borneol Drugs 0.000 description 3
- CKDOCTFBFTVPSN-UHFFFAOYSA-N borneol Natural products C1CC2(C)C(C)CC1C2(C)C CKDOCTFBFTVPSN-UHFFFAOYSA-N 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 230000006378 damage Effects 0.000 description 3
- DTGKSKDOIYIVQL-UHFFFAOYSA-N dl-isoborneol Natural products C1CC2(C)C(O)CC1C2(C)C DTGKSKDOIYIVQL-UHFFFAOYSA-N 0.000 description 3
- 210000003278 egg shell Anatomy 0.000 description 3
- 231100000013 eye irritation Toxicity 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- 230000002757 inflammatory effect Effects 0.000 description 3
- 230000004054 inflammatory process Effects 0.000 description 3
- 230000002401 inhibitory effect Effects 0.000 description 3
- 230000003020 moisturizing effect Effects 0.000 description 3
- 210000003205 muscle Anatomy 0.000 description 3
- 239000013641 positive control Substances 0.000 description 3
- 229930004725 sesquiterpene Natural products 0.000 description 3
- 238000003860 storage Methods 0.000 description 3
- 230000036572 transepidermal water loss Effects 0.000 description 3
- 241000123835 Ampelopsis japonica Species 0.000 description 2
- 241000092665 Atractylodes macrocephala Species 0.000 description 2
- 241001313857 Bletilla striata Species 0.000 description 2
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 2
- 238000002965 ELISA Methods 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 241000287828 Gallus gallus Species 0.000 description 2
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical group NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 2
- 206010020751 Hypersensitivity Diseases 0.000 description 2
- 241000112528 Ligusticum striatum Species 0.000 description 2
- 241001071917 Lithospermum Species 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 210000001643 allantois Anatomy 0.000 description 2
- 208000026935 allergic disease Diseases 0.000 description 2
- 230000007815 allergy Effects 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 230000000740 bleeding effect Effects 0.000 description 2
- 239000006143 cell culture medium Substances 0.000 description 2
- 229940059958 centella asiatica extract Drugs 0.000 description 2
- 230000015271 coagulation Effects 0.000 description 2
- 238000005345 coagulation Methods 0.000 description 2
- 230000011382 collagen catabolic process Effects 0.000 description 2
- 230000037319 collagen production Effects 0.000 description 2
- 238000013329 compounding Methods 0.000 description 2
- 238000000354 decomposition reaction Methods 0.000 description 2
- 230000007547 defect Effects 0.000 description 2
- 230000006866 deterioration Effects 0.000 description 2
- 210000001339 epidermal cell Anatomy 0.000 description 2
- 210000002615 epidermis Anatomy 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 239000001649 glycyrrhiza glabra l. absolute Substances 0.000 description 2
- 238000005469 granulation Methods 0.000 description 2
- 230000003179 granulation Effects 0.000 description 2
- 230000035876 healing Effects 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 238000009776 industrial production Methods 0.000 description 2
- 238000007689 inspection Methods 0.000 description 2
- BEJNERDRQOWKJM-UHFFFAOYSA-N kojic acid Chemical compound OCC1=CC(=O)C(O)=CO1 BEJNERDRQOWKJM-UHFFFAOYSA-N 0.000 description 2
- 229960004705 kojic acid Drugs 0.000 description 2
- WZNJWVWKTVETCG-UHFFFAOYSA-N kojic acid Natural products OC(=O)C(N)CN1C=CC(=O)C(O)=C1 WZNJWVWKTVETCG-UHFFFAOYSA-N 0.000 description 2
- 235000020725 licorice root extract Nutrition 0.000 description 2
- 229940051810 licorice root extract Drugs 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 210000002540 macrophage Anatomy 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 210000004379 membrane Anatomy 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- 239000002244 precipitate Substances 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 230000035484 reaction time Effects 0.000 description 2
- 230000002040 relaxant effect Effects 0.000 description 2
- 230000028327 secretion Effects 0.000 description 2
- 150000004354 sesquiterpene derivatives Chemical class 0.000 description 2
- 238000013112 stability test Methods 0.000 description 2
- 238000006467 substitution reaction Methods 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 230000002195 synergetic effect Effects 0.000 description 2
- DNIAPMSPPWPWGF-VKHMYHEASA-N (+)-propylene glycol Chemical compound C[C@H](O)CO DNIAPMSPPWPWGF-VKHMYHEASA-N 0.000 description 1
- YPFDHNVEDLHUCE-UHFFFAOYSA-N 1,3-propanediol Substances OCCCO YPFDHNVEDLHUCE-UHFFFAOYSA-N 0.000 description 1
- 229940035437 1,3-propanediol Drugs 0.000 description 1
- NIXOWILDQLNWCW-UHFFFAOYSA-N Acrylic acid Chemical compound OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 1
- 102000010637 Aquaporins Human genes 0.000 description 1
- 108010063290 Aquaporins Proteins 0.000 description 1
- 241000132012 Atractylodes Species 0.000 description 1
- 241000186000 Bifidobacterium Species 0.000 description 1
- 235000009024 Ceanothus sanguineus Nutrition 0.000 description 1
- 244000189548 Chrysanthemum x morifolium Species 0.000 description 1
- 102000012422 Collagen Type I Human genes 0.000 description 1
- 108010022452 Collagen Type I Proteins 0.000 description 1
- 231100000635 Draize test Toxicity 0.000 description 1
- 208000003556 Dry Eye Syndromes Diseases 0.000 description 1
- 206010013774 Dry eye Diseases 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 1
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 1
- 206010018910 Haemolysis Diseases 0.000 description 1
- 102000003777 Interleukin-1 beta Human genes 0.000 description 1
- 108090000193 Interleukin-1 beta Proteins 0.000 description 1
- 102000004125 Interleukin-1alpha Human genes 0.000 description 1
- 108010082786 Interleukin-1alpha Proteins 0.000 description 1
- 240000003553 Leptospermum scoparium Species 0.000 description 1
- 241000244365 Ligusticum sinense Species 0.000 description 1
- 235000015459 Lycium barbarum Nutrition 0.000 description 1
- 241000219926 Myrtaceae Species 0.000 description 1
- 240000002853 Nelumbo nucifera Species 0.000 description 1
- 235000006508 Nelumbo nucifera Nutrition 0.000 description 1
- 235000006510 Nelumbo pentapetala Nutrition 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 240000002134 Pentadesma butyracea Species 0.000 description 1
- 235000000857 Pentadesma butyracea Nutrition 0.000 description 1
- 208000003251 Pruritus Diseases 0.000 description 1
- 244000007853 Sarothamnus scoparius Species 0.000 description 1
- 208000028990 Skin injury Diseases 0.000 description 1
- 206010040880 Skin irritation Diseases 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 229920002125 Sokalan® Polymers 0.000 description 1
- 241001369613 Stephania tetrandra Species 0.000 description 1
- 102000003566 TRPV1 Human genes 0.000 description 1
- 206010043189 Telangiectasia Diseases 0.000 description 1
- 101150016206 Trpv1 gene Proteins 0.000 description 1
- 241001135917 Vitellaria paradoxa Species 0.000 description 1
- 235000018936 Vitellaria paradoxa Nutrition 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 238000003915 air pollution Methods 0.000 description 1
- 230000000172 allergic effect Effects 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 230000003266 anti-allergic effect Effects 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000003064 anti-oxidating effect Effects 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 230000001914 calming effect Effects 0.000 description 1
- 229960001631 carbomer Drugs 0.000 description 1
- 239000004359 castor oil Substances 0.000 description 1
- 235000019438 castor oil Nutrition 0.000 description 1
- 230000005779 cell damage Effects 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 208000037887 cell injury Diseases 0.000 description 1
- 210000002421 cell wall Anatomy 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 229960005188 collagen Drugs 0.000 description 1
- 210000000795 conjunctiva Anatomy 0.000 description 1
- 239000008358 core component Substances 0.000 description 1
- 230000007797 corrosion Effects 0.000 description 1
- 238000005260 corrosion Methods 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 230000001086 cytosolic effect Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 1
- 229960003957 dexamethasone Drugs 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 238000002845 discoloration Methods 0.000 description 1
- 230000005782 double-strand break Effects 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 239000000428 dust Substances 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 229940012466 egg shell membrane Drugs 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 231100000321 erythema Toxicity 0.000 description 1
- 238000004299 exfoliation Methods 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 210000002744 extracellular matrix Anatomy 0.000 description 1
- 230000004438 eyesight Effects 0.000 description 1
- 230000001815 facial effect Effects 0.000 description 1
- 235000019197 fats Nutrition 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 229930182478 glucoside Natural products 0.000 description 1
- 125000002791 glucosyl group Chemical group C1([C@H](O)[C@@H](O)[C@H](O)[C@H](O1)CO)* 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 1
- 229930182470 glycoside Natural products 0.000 description 1
- 239000004519 grease Substances 0.000 description 1
- 230000012447 hatching Effects 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000008588 hemolysis Effects 0.000 description 1
- 229960001340 histamine Drugs 0.000 description 1
- 230000001976 improved effect Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000000415 inactivating effect Effects 0.000 description 1
- 230000028709 inflammatory response Effects 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 239000002085 irritant Substances 0.000 description 1
- 231100000021 irritant Toxicity 0.000 description 1
- 230000007803 itching Effects 0.000 description 1
- 229940064221 ligusticum wallichii root extract Drugs 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 229920002521 macromolecule Polymers 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 231100000344 non-irritating Toxicity 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 230000008447 perception Effects 0.000 description 1
- 239000012466 permeate Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 230000008832 photodamage Effects 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 229920000166 polytrimethylene carbonate Polymers 0.000 description 1
- 230000008092 positive effect Effects 0.000 description 1
- 244000144977 poultry Species 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 230000009703 regulation of cell differentiation Effects 0.000 description 1
- 230000021014 regulation of cell growth Effects 0.000 description 1
- 230000012760 regulation of cell migration Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 230000018040 scab formation Effects 0.000 description 1
- 230000002000 scavenging effect Effects 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 230000037307 sensitive skin Effects 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 230000036620 skin dryness Effects 0.000 description 1
- 230000037394 skin elasticity Effects 0.000 description 1
- 230000036556 skin irritation Effects 0.000 description 1
- 231100000475 skin irritation Toxicity 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 230000035882 stress Effects 0.000 description 1
- 230000036561 sun exposure Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 208000009056 telangiectasis Diseases 0.000 description 1
- 238000010257 thawing Methods 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 239000000273 veterinary drug Substances 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 239000000341 volatile oil Substances 0.000 description 1
- 230000037314 wound repair Effects 0.000 description 1
- 239000000230 xanthan gum Substances 0.000 description 1
- 229920001285 xanthan gum Polymers 0.000 description 1
- 229940082509 xanthan gum Drugs 0.000 description 1
- 235000010493 xanthan gum Nutrition 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
- A61K8/65—Collagen; Gelatin; Keratin; Derivatives or degradation products thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/34—Alcohols
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/37—Esters of carboxylic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/60—Sugars; Derivatives thereof
- A61K8/602—Glycosides, e.g. rutin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
- A61K8/73—Polysaccharides
- A61K8/735—Mucopolysaccharides, e.g. hyaluronic acid; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9728—Fungi, e.g. yeasts
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9783—Angiosperms [Magnoliophyta]
- A61K8/9789—Magnoliopsida [dicotyledons]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9783—Angiosperms [Magnoliophyta]
- A61K8/9794—Liliopsida [monocotyledons]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/98—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution of animal origin
- A61K8/981—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution of animal origin of mammals or bird
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/98—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution of animal origin
- A61K8/987—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution of animal origin of species other than mammals or birds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/99—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from microorganisms other than algae or fungi, e.g. protozoa or bacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/16—Emollients or protectives, e.g. against radiation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/005—Preparations for sensitive skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/08—Anti-ageing preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
- A61K2800/48—Thickener, Thickening system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
- A61K2800/51—Chelating agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
- A61K2800/52—Stabilizers
- A61K2800/522—Antioxidants; Radical scavengers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
- A61K2800/52—Stabilizers
- A61K2800/524—Preservatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
- A61K2800/59—Mixtures
- A61K2800/592—Mixtures of compounds complementing their respective functions
- A61K2800/5922—At least two compounds being classified in the same subclass of A61K8/18
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/80—Process related aspects concerning the preparation of the cosmetic composition or the storage or application thereof
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Birds (AREA)
- Epidemiology (AREA)
- Dermatology (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Organic Chemistry (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biotechnology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Emergency Medicine (AREA)
- Botany (AREA)
- Zoology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Gerontology & Geriatric Medicine (AREA)
- Toxicology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Cosmetics (AREA)
Abstract
本发明公开了含重组胶原蛋白具有修护舒缓功效的组合物、含有该组合物的眼霜及制备方法和应用,属于护肤品技术领域。所述具有修护舒缓功效的组合物的功效成分如下:1~10份重组胶原蛋白、1~10份透明质酸钠、1~5份二裂酵母发酵产物溶胞物、1~15份甘油葡糖苷、1~10份红没药醇、1~15份八宝精粹原液、1~15份松红梅复核精粹。该组合物具有较好的皮肤渗透率;基于所述组合物制备得到的眼霜不仅具有显著的修护皮肤屏障、舒缓皮肤炎症功效,还具有刺激性小、安全性高的优势,非常适合眼部肌肤受损的人群使用,具有较好的市场应用前景。
Description
技术领域
本发明涉及护肤品技术领域,具体涉及一种含重组胶原蛋白具有修护舒缓功效的组合物、含有该组合物的眼霜及制备方法和应用。
背景技术
眼部周围的皮肤是人体皮肤最薄弱的部位,其表皮和真皮的厚度远远不如面部皮肤的厚度,很容易受到外界的伤害。随着年龄的增长和生活压力的增加,熬夜、长时间面对电脑、环境中的阳光、人工光线照射、空气污染以及粉尘、颗粒等因素会导致眼周肌肤加速老化,造成肌肤损伤,破坏眼周肌肤屏障,导致眼周肌肤水分流失,外界刺激易深入伤害眼周肌肤,极易产生瘙痒、刺痛、烧灼、紧绷等肌肤敏感症状。普遍研究认为这些症状的发生是一种涉及皮肤屏障-神经血管-免疫炎症的复杂过程,因此,解决上述眼部肌肤敏感受损问题可以从修护皮肤屏障、舒缓皮肤炎症反应这两个主要的方面着手。
目前市场上常见的针对敏感性皮肤的产品多以舒缓皮肤炎症反应或修护皮肤屏障作为产品的功能,较少基于两个方面进行综合考虑,效果不甚理想。例如公开号为CN114272179A的专利申请文献公开了一种用于皮肤修复的组合物,该组合物包括以下原料:卡波姆、黄原胶、透明质酸钠、甘油、PEG-60氢化蓖麻油、重组胶原蛋白、甘草根提取物、积雪草提取物、1,2-己二醇、对羟基苯乙酮、苯氧乙醇、紫草根提取物,其余为去离子水,其利用重组胶原蛋白的保湿修复作用、甘草根提取物的抗炎抗过敏作用、积雪草提取物的紧致修复作用、紫草根提取物的抗炎修复作用,在多种皮肤修复原料的复配协同下具有强效修复功效。
但是,上述用于皮肤修复的组合物中的主要活性成分重组胶原蛋白作为一种大分子蛋白,将其外用基本只能到达皮肤表皮层,并不能透过皮肤基质到达真皮层,皮肤渗透率差,其在功效性敷料及功效性护肤品等皮肤外用产品上的应用效果十分有限。由此可知,现有技术中含重组胶原蛋白的功效性敷料及功效性护肤品等皮肤外用产品普遍存在皮肤渗透性差、应用效果不明显等缺陷。
因此,提高含重组胶原蛋白等大分子蛋白的皮肤渗透性、提高其应用效率,是当前所属领域技术人员急需解决的技术难题。
发明内容
针对现有技术存在的不足,本发明的目的之一在于提供含重组胶原蛋白具有修护舒缓功效的组合物,该组合物具有较好的皮肤渗透率,不仅具有显著的修护皮肤屏障、舒缓皮肤炎症功效,还具有刺激性小、安全性高的优势。
本发明的第二个目的在于提供含有上述组合物的具有修护舒缓功效的眼霜,该眼霜的稳定性高、刺激性小。
本发明的第三个目的在于提供一种上述眼霜的制备方法,该制备方法简单高效,适合工业化生产应用。
为了实现上述目的,本发明采用如下技术方案:
第一方面,本发明提供一种含重组胶原蛋白具有修护舒缓功效的组合物,以重量份计,包括以下制备原料:
上述技术方案中,重组胶原蛋白作为细胞外基质参与细胞生长、分化、迁移、代谢的调功,促进细胞生长,具有加速创面修复、抑制痂痕形成功能,具有较好的修护功效,且重组胶原蛋白中的胶原肽可以在肌肤表面形成薄膜,具有较好的皮肤屏障功效,因此,重组胶原蛋白对受损肌肤具有较好的修护皮肤屏障作用。
透明质酸钠不仅是一种较好的保湿剂,还具有促进表皮细胞的增殖和分化以及清除氧自由基的作用,可加速表皮细胞的再生,促进受损肌肤修复,使皮肤细嫩光滑,富有弹性。
二裂酵母发酵产物溶胞物可促进DNA的损伤修复,防止双链断裂形成的作用(微核),同时能有效保护皮肤,使其保持活力,减少慢性光损伤的风险,对于受损肌肤的修复有很重大的积极作用;二裂酵母还具有很好的抗炎舒缓作用,还能缓解皮肤干燥和敏感性,缓解应激状态诸如肌肤发红、过敏等状态,并能增强皮肤屏障的抵抗力,特别是环境变化的抵抗能力。
甘油葡糖苷是一种由葡萄糖基和甘油通过糖苷键连接而成的糖苷化合物,可以深入真皮层,具有长效保湿、修复、舒缓作用,其多羟基结构可保持细胞水分、在细胞层面通过促进水通道蛋白合成为细胞全面补水,具有较好的保湿作用;甘油葡糖苷还能促进I型胶原蛋白表达,进而增强肌肤弹性和胶原蛋白,促进皮肤屏障修复;此外,甘油葡糖苷还能显著降低IL-1β、IL-1α等炎症因子的释放量,显著提高细胞愈合率,具有较好的抗炎舒缓功效。
红没药醇从菊类植物中提取,有明显的抗炎抑菌作用,其作为活性成分以保护和护理过敏性皮肤,降低皮肤炎症,提高皮肤的抗刺激能力,具有修护皮肤屏障、舒缓皮肤炎症、缓和刺激和抗过敏功效。红没药醇还能抑制皮肤中负责胶原蛋白分解的酶,防止胶原蛋白分解,同时刺激胶原蛋白的产生。
松红梅复核精粹的核心成分为松红梅,属桃金娘科薄子木属,别名扫帚叶澳洲茶树,松红梅花色鲜艳、富含倍半萜烯、倍半萜醇、倍半萜酮类成分为主的精油,以野生为主。现代药理试验表明,松红梅复合精萃通过松红梅、粉防己、莲花等成分的协同作用,能抑制TRPV1和NO生成、抑制组胺信号通路,对外部刺激物和炎症引起的局部皮肤刺痛、红斑及毛细血管扩张有较强的抑制作用,具有较好的抗炎舒缓功效。
八宝精粹原液包括川芎根提取物、茯苓菌核提取物、白术根提取物、白及根提取物、白蔹根提取物、人工牛黄、珍珠提取物及冰片,其中,牛黄具有一定的抗氧化功能,冰片起防腐生肌之效,珍珠起明目、安神、息风、生肌敛疮之效,配合白蔹、白及、白术、茯苓、川芎五味,起到了较好的抗氧化、活血化瘀的功效,能够有效预防细胞损伤和修护皮肤屏障。
具体来说,本发明中八宝精粹原液的产品构成为:0.8wt%川芎(LIGUSTICUMCHUANXIONG)根提取物、0.5wt%茯苓(PORIA COCOS)菌核提取物、0.5wt%白术(ATRACTYLODES MACROCEPHALA)根提取物、0.3wt%白及(BLETILLA STRIATA)根提取物、0.3wt%白蔹(AMPELOPSIS JAPONICA)根提取物、0.05wt%人工牛黄、1wt%珍珠提取物、0.05wt%冰片,1wt%1,2-己二醇、5wt%丁二醇、0.5wt%苯氧乙醇、0.1wt%乙基己基甘油、89.9wt%水。本发明中八宝精粹原液由上述原料混合均匀后,过滤灭菌制得。
作为本发明技术方案的进一步优选,一种含重组胶原蛋白具有修护舒缓功效的组合物,以重量份计,包括以下制备原料:
第二方面,本发明提供一种眼霜,其由上述组合物以及辅料制备得到。也即为了改良感官性、赋予皮肤营养、防止品质劣化等,可以在不损害本发明效果的范围内,在本发明所述组合物中可根据需要适当添加除上述成分以外一般用于眼部化妆品中的各种成分。
作为本发明技术方案的进一步优选,所述辅料选自多元醇、保湿剂、润肤剂、乳化剂、增稠剂、抗氧化剂、金属离子螯合剂、防腐剂、pH调节剂、抗氧化剂、去离子水中的一种或多种。
作为本发明技术方案的进一步优选,所述乳化剂为鲸蜡醇棕榈酸酯/山梨坦棕榈酸酯/山梨坦橄榄油酸酯与鲸蜡硬脂醇橄榄油酸酯/山梨坦橄榄油酸酯的复配乳化剂;所述润肤剂选自牛油果树(BUTYROSPERMUM PARKII)果脂、植物甾醇异硬脂酸酯、氢化聚癸烯、异壬酸异壬酯、聚二甲基硅氧烷、鲸蜡硬脂醇、异十六烷、环五聚二甲基硅氧烷中的一种或多种;所述增稠剂选自季戊四醇二硬脂酸酯、丙烯酸羟乙酯/丙烯酰二甲基牛磺酸钠共聚物、鲸蜡硬脂醇、蜂蜡中的一种或多种。需要特别强调的是,鲸蜡醇棕榈酸酯/山梨坦棕榈酸酯/山梨坦橄榄油酸酯与鲸蜡硬脂醇橄榄油酸酯/山梨坦橄榄油酸酯的复配比例为1:1~3,优选为1:2。
作为本发明技术方案的进一步优选,所述金属离子螯合剂选自EDTA二钠、EDTA、EDTA四钠中的一种或多种;所述多元醇选自甘油、丙二醇、丁二醇、山梨醇、双丙甘醇、1,3-丙二醇、戊二醇、己二醇中的一种或多种;所述抗氧化剂选自生育酚类、二丁基羟基甲苯、丁基羟基茴香醚、没食子酸酯类中的一种或多种;所述防腐剂选自苯氧乙醇、乙基己基甘油、氯苯甘醚、羟苯甲酯、对羟基苯乙酮、羟苯丙酯、1,2-己二醇、山梨坦辛酸酯中的一种或多种。
第三方面,本发明还提供一种上述眼霜的制备方法,包括如下步骤:
(1)将第一部分多元醇、金属离子螯合剂、透明质酸钠、去离子水混合后,加热分散均匀,得到混合物1;
(2)将润肤剂、保湿剂、乳化剂、第一部分增稠剂、抗氧化剂、红没药醇、第一部分防腐剂加热搅拌均匀后加入到步骤(1)所得混合物1中,随后均质处理后再搅拌,得到混合物2;
(3)将第二部分增稠剂与第二部分多元醇混合搅拌均匀后加入到步骤(2)所得混合物2中,加热搅拌、均质处理后降温,得混合物3;
(4)将重组胶原蛋白、甘油葡糖苷、八宝精粹原液、松红梅复核精粹、二裂酵母发酵产物溶胞物混匀后加入步骤(3)所得混合物3中,搅拌均匀后降温,得混合物4;
(5)将第二部分防腐剂混匀后加入步骤(4)所得混合物4中,搅拌均匀后进行均质、抽真空处理,然后降温出料,即得所述眼霜。
作为本发明技术方案的进一步优选,步骤(1)、(2)中加热搅拌温度为75~90℃;步骤(3)中降温至40~50℃;步骤(4)中降温至35~45℃。
作为本发明技术方案的进一步优选,步骤(2)、(3)中所述均质处理的转速为1000~6000rpm。
第四方面,本发明还提供一种上述组合物在制备眼部护理产品中的应用。可以理解的是,前述眼霜的制备只是应用的一种形式,还可以是眼部精华液、眼膜等产品。
与现有技术相比,本发明具有如下有益效果:
1、本发明提供的含重组胶原蛋白的组合物,优选重组胶原蛋白、透明质酸钠、二裂酵母发酵产物溶胞物、甘油葡糖苷、红没药醇、八宝精粹原液、松红梅复核精粹复配,该组合物具有较好的皮肤渗透率,不仅具有显著的修护皮肤屏障、舒缓皮肤炎症功效,还具有刺激性小、安全性高的优势。
2、本发明利用甘油葡糖苷作为一种能渗入皮肤真皮层的天然细胞激活剂,不仅可以帮助提高大分子化合物重组胶原蛋白、透明质酸钠的皮肤渗透率,还可以促进胶原蛋白在体内的表达;利用红没药醇抑制皮肤中负责胶原蛋白分解的酶,防止胶原蛋白分解,同时刺激胶原蛋白的产生。再辅以修复舒缓成分二裂酵母发酵产物溶胞物、抗炎成分松红梅复合精粹、皮肤修复成分八宝精粹原液,在多成分的协同作用下进一步增强了本发明组合物的修护舒缓功效。
3、本发明选用的二裂酵母发酵产物溶胞物是经双歧杆菌培养、灭活及分解得到代谢产物、细胞质片段、细胞壁组分及多糖复合体,同时在发酵的过程中同时含有丰富的维他命、矿物质、氨基酸和曲酸,但其中的曲酸会增加皮肤刺激,易导致皮肤产生发红刺痛等副作用,一般不适合敏感肌使用。但是本发明所述组合物利用各功效成分的协同以及调控各成分的用量,降低了组合物的刺激性,使其非常适合皮肤受损的敏感肌使用。
4、本发明加入鲸蜡醇棕榈酸酯/山梨坦棕榈酸酯/山梨坦橄榄油酸酯与鲸蜡硬脂醇橄榄油酸酯/山梨坦橄榄油酸酯的复配物作为乳化剂,与其他成分协同作用,大大提高了产品的稳定性。制得的产品手感细腻、涂抹无颗粒、易于推开,在常温储存和高低温循环条件下无明显变色变味,膏体无出水出油等分层现象,可存放较长时间不变质,具有较强的应用价值。
5、本发明所述的眼霜,其制备方法简单高效,适合工业化生产应用。
附图说明
图1为鸡胚绒毛尿囊膜试验中实施例1和对比例1的鸡胚刺激对比图,其中,A为无刺激的实施例1,B为中刺激的对比例1。
具体实施方式
下面将结合本发明实施方式,对本发明实施方式中的技术方案进行清楚、完整地描述,显然,所描述的实施方式仅仅是本发明一部分实施方式,而不是全部的实施方式。基于本发明中的实施方式,本领域普通技术人员在没有做出创造性劳动前提下所获得的所有其他实施方式,都属于本发明保护的范围。
需要特别说明的是,本发明中部分物质信息如下:
本发明中所用重组胶原蛋白购自江苏江山聚源生物技术有限公司;
本发明中所用八宝精粹原液为马应龙大健康有限公司自产;
本发明中所用松红梅复合精萃购自广州伽能生物科技有限公司;
本发明中所用鲸蜡硬脂醇橄榄油酸酯/山梨坦橄榄油酸酯的商品名为Olivem1000;
本发明中所用丙烯酸羟乙酯/丙烯酰二甲基牛磺酸钠共聚物的商品名为SEPINOVTMWEO;
本发明中所用苯氧乙醇/乙基己基甘油的商品名为euxyl PE 9010。
实施例1
一种含重组胶原蛋白具有修护舒缓功效的组合物,以重量计,包括以下制备原料:
本实施例还提供一种上述组合物的制备方法,包括:先将配方量的红没药醇溶于25g丁二醇中,随后加入45g去离子水及配方量的其余各组分进行混合,即得所述组合物。
实施例2
一种含重组胶原蛋白具有修护舒缓功效的组合物,以重量计,包括以下制备原料:
本实施例还提供一种上述组合物的制备方法,包括:先将配方量的红没药醇溶于20g丁二醇中,随后加入50g去离子水及配方量的其余各组分进行混合,即得所述组合物。
实施例3
一种含重组胶原蛋白具有修护舒缓功效的组合物,以重量计,包括以下制备原料:
本实施例还提供一种上述组合物的制备方法,包括:先将配方量的红没药醇溶于30g丁二醇中,随后加入35g去离子水及配方量的其余各组分进行混合,即得所述组合物。
实施例4
一种具有修护舒缓功效的眼霜,以重量计,由以下原料制成:
表1实施例4中原料组成
本实施例还提供一种上述眼霜的制备方法,包括如下步骤:
(1)将A组分加入到乳化锅中,加热至80℃,溶解至各组分分散均匀,得到混合物1;
(2)将B组分先加入油锅中,加热至85℃,搅拌至分散均匀,然后将其匀速加入到步骤(1)所得混合物1中,以3000rpm的速度进行均质乳化处理3min,再以400rpm的速度搅拌,得到混合物2;
(3)将C组分预先混匀后再加入步骤(2)所得混合物2中,以3000rpm的速度均质处理10min后再降温至45℃,得到混合物3;
(4)将D组分混匀后加入步骤(3)所得混合物3中,搅拌均匀、降温至40℃,得到混合物4;
(5)将E组分混匀后加入步骤(4)所得混合物4中,搅拌均匀后进行均质、抽真空处理,然后降温至35℃出料,再降至常温即得所述眼霜。
实施例5
一种具有修护舒缓功效的眼霜,以重量计,由以下原料制成:
表2实施例5中原料组成
本实施例还提供一种上述眼霜的制备方法,包括如下步骤:
(1)将A组分加入到乳化锅中,加热至80℃,溶解至各组分分散均匀,得到混合物1;
(2)将B组分先加入油锅中,加热至85℃,搅拌至分散均匀,然后将其匀速加入到步骤(1)所得混合物1中,以3000rpm的速度进行均质乳化处理3min,再以400rpm的速度搅拌,得到混合物2;
(3)将C组分预先混匀后再加入步骤(2)所得混合物2中,以3000rpm的速度均质处理10min后再降温至45℃,得到混合物3;
(4)将D组分混匀后加入步骤(3)所得混合物3中,搅拌均匀、降温至40℃,得到混合物4;
(5)将E组分混匀后加入步骤(4)所得混合物4中,搅拌均匀后进行均质、抽真空处理,然后降温至35℃出料,再降至常温即得所述眼霜。
实施例6
一种具有修护舒缓功效的眼霜,以重量计,由以下原料制成:
表3实施例6中原料组成
本实施例还提供一种上述眼霜的制备方法,包括如下步骤:
(1)将A组分加入到乳化锅中,加热至80℃,溶解至各组分分散均匀,得到混合物1;
(2)将B组分先加入油锅中,加热至85℃,搅拌至分散均匀,然后将其匀速加入到步骤(1)所得混合物1中,以3000rpm的速度进行均质乳化处理3min,再以400rpm的速度搅拌,得到混合物2;
(3)将C组分预先混匀后再加入步骤(2)所得混合物2中,以3000rpm的速度均质处理10min后再降温至45℃,得到混合物3;
(4)将D组分混匀后加入步骤(3)所得混合物3中,搅拌均匀、降温至40℃,得到混合物4;
(5)将E组分混匀后加入步骤(4)所得混合物4中,搅拌均匀后进行均质、抽真空处理,然后降温至35℃出料,再降至常温即得所述眼霜。
对比例1
一种单一化合物,所述化合物为二裂酵母发酵产物溶胞物。
对比例2
一种含重组胶原蛋白具有修护舒缓功效的组合物,以重量计,由以下原料制成:
本对比例还提供一种上述组合物的制备方法,包括:先将配方量的红没药醇溶于25g丁二醇中,随后加入45g去离子水及配方量的其余各组分进行混合,即得所述组合物。
对比例3
一种含重组胶原蛋白具有修护舒缓功效的组合物,以重量计,由以下原料制成:
本对比例还提供一种上述组合物的制备方法,包括:先将配方量的红没药醇溶于20g丁二醇中,随后加入50g去离子水及配方量的其余各组分进行混合,即得所述组合物。
对比例4:
与实施例4相比,区别仅在于B组分中不加鲸蜡醇棕榈酸酯/山梨坦棕榈酸酯/山梨坦橄榄油酸酯,其他组分及制备方法均一致。
对比例5:
与实施例4相比,区别仅在于D组分中不加甘油葡糖苷,其他组分及制备方法均一致。
对比例6:
与实施例4相比,区别仅在于B组分中不加红没药醇,其他组分及制备方法均一致。
试验例1
对上述制备得到组合物进行眼刺激性体外试验。鸡胚绒毛尿囊膜试验(HET-CAMTest)是欧洲替代方法认证中心(ECVAM)认证的测试产品刺激性的试验方法,是目前化妆品及化学品眼刺激性体外试验的主要研究方法之一,可用来评价多种物质的刺激性。
鸡胚尿囊膜表面血管丰富,可以看作一个完整的生物体,不像单纯在细胞系上进行的试验,在作为眼刺激替代方法上有较好的潜力。该方法基本原理是鸡胚尿囊膜绒毛膜(CAM)是鸡胚的呼吸膜,血管丰富,紧贴于蛋壳膜下,可看为是一个血管丰富而无感知的系统。利用CAM与兔结膜结构相似的特性,可作为眼刺激性的筛选方法,通过观察CAM暴露后血管的变化(出血、溶血、凝血)检测化学物质对CAM的损伤,可以评价化学物可能的刺激性。HET-CAM试验作为眼刺激Draize试验的替代方法,已得到国际性验证。
试验方法:
①鸡蛋选择:选用SPF级白莱杭鸡受精鸡蛋(济南赛斯家禽科技有限公司购买)。鸡蛋质量符合相关标准的要求,供应商应具有农业部门认可的《兽药生产、检验用SPF鸡(蛋)定点生产企业》资格。鸡蛋应新鲜、干净、完好,质量50g-60g。孵化至4日龄时,应照蛋检查,弃去未受精的鸡胚,破壳或薄壳鸡胚也不能使用。
②试验用鸡胚准备:购买SPF鸡胚,气室朝上置于孵化箱,孵化温度37.5℃±0.5℃,相对湿度60%±5%,转盘频率1次/30min,孵化至9日龄,用照蛋器检查孵化情况,未受精、无活性、有缺陷、畸形、破壳或薄壳鸡胚均不可使用。
③尿囊膜(CAM)制备:9日龄鸡胚照蛋检查,并标记气室位置;用镊子剥去气室处蛋壳部分,滴加0.9%NaCl溶液湿润内膜后,用镊子剥去,不得破坏血管,否则应弃用。
④正式实验:根据受试物特性,选择试验方法。透明液体,选择反应时间法。此组合物为透明液体,采用反应时间法。取受试物0.3ml直接滴加于CAM表面,作用5min,观察并记录出血、凝血、血管融解出现的时间(s)。重复6只鸡胚。
受试样品:实施例1~3、对比例1~3制得的组合物。
试验结果:鸡胚绒毛尿囊膜试验的刺激评分法结果评价见表4,实施例和对比例制得的组合物刺激性结果见表5。
表4刺激评分法结果评价
刺激评分 | 刺激性分类 |
IS<1 | 无刺激性 |
1≤IS≤5 | 轻刺激性 |
5≤IS≤9 | 中度刺激性 |
IS≥10 | 强刺激性/腐蚀性 |
表5实施例和对比例制得的组合物刺激性结果
编号 | 鸡胚绒毛尿囊膜刺激分数(IS) | 刺激强度 |
实施例1 | 0.6 | 无刺激性 |
实施例2 | 0.8 | 无刺激性 |
实施例3 | 0.5 | 无刺激性 |
对比例1 | 6 | 中度刺激性 |
对比例2 | 4 | 轻/中度刺激性 |
对比例3 | 5 | 轻/中度刺激性 |
由表5可以看出,对比例1单独测试二裂酵母发酵产物溶胞物对鸡胚存在中度刺激性,其不适合角质层薄弱的人群及敏感肌人群,这是由于二裂酵母有加速角质层脱落的作用、加速角质层代谢。实施例1~3制备的组合物鸡胚刺激评分法均小于1,呈无刺激性,这是由于本发明将二裂酵母发酵产物溶胞物与其他组分的复配之后,其刺激性有所降低。对比例2和3提高了二裂酵母发酵产物溶胞物的用量,其制备的组合物鸡胚刺激评分法就显示了轻/中度刺激性。
试验例2
分别对实施例4和对比例4制得的眼霜进行稳定性性能考察,具体测试方法和结果如下:
测试方法:将40~50g重膏体装入50mL透明玻璃瓶,6只平行样,分别放在低温-7℃、低温4℃、循环-7℃/45℃/24h、高温45℃、常温25℃条件下考察30天,另外一只样品放置在高温60℃条件下考察7天。
稳定性判定标准:内部质量控制标准,所有样品恢复室温后,与4℃样品对比,常温储存和高低温循环无明显变色变味,膏体无出水出油等分层现象,涂抹无颗粒或析出物,视为稳定。
稳定性测试具体结果评判如下表6所示:
表6实施例4和对比例4制得眼霜的稳定性测试结果
试验结果表明:本发明实施例4制得的产品手感细腻、涂抹无颗粒、易于推开,在常温储存和高低温循环无明显变色变味,膏体无出水出油等分层现象,稳定性考察均无异常,产品稳定性较好。而对比例4制得的产品油脂感较厚重、吸收不够快,经过高低温循环及高温环境后,膏体出现析出物,涂抹有颗粒感,产品稳定性较差。
试验例3
本发明采用经表皮水分流失(TEWL)测试评价实施例和对比例制得的眼霜的修护功效,采用的仪器设备、测试方法以及测试结果如下:
仪器设备:皮肤表面水分流失仪Tewameter TM 300(Courage&Khazaka,德国)。
检测方法:随机选取选择年龄18-60岁,眼部皮肤干燥、粗糙皮肤屏障脆弱的受试者30人,分为3组,每组10人,分别将实施例4和对比例5~6的待测样品,均匀涂于每组受试者眼周肌肤10-15min,轻揉至吸收,早晚各使用1次。整个测试期间不能进行长时间的日晒、户外运动、旅游等,整个测试期间不得使用与产品功效相似的化妆品或者药品,测试期间受试者不得改变日常护理习惯。
统计方法:每位受试者测试3次取平均值,再利用SPSS软件进行统计分析,其中,得到的TEWL值越低,说明经皮水分流失少。
测试结果:见表7所示。
表7受试者皮肤使用产品前后的经皮水分流失量结果(X±S,n=10)
(与使用产品前比较,*P<0.05,**P<0.01)
由表7可知,使用实施例产品14天后,眼周经皮水分流失量就表现出极显著降低(p<0.01),使用产品28天后,经皮水分流失量进一步降低,该产品修护效果好,起效快;使用对比例产品14天后,眼周经皮水分流失量无显著性差异,由此可知,本发明实施例产品对眼部干燥、粗糙、脆弱皮肤的修护效果远优于对比例产品。
试验例4
本发明参照标准《T/SHRH 034-2020化妆品舒缓功效测试-体外TNF-α炎症因子含量测定脂多糖诱导巨噬细胞RAW264.7测试方法》测定实施例和对比例制得眼霜的舒缓功效。具体利用细菌脂多糖(LPS)诱导巨噬细胞系RAW264.7分泌炎性因子TNF-α的原理,通过测定不同受试物作用后TNF-α含量的差异,评价受试物抑制TNF-α分泌的作用。具体的评价指标为TNF-α含量及TNF-α抑制率,其中,TNF-α含量采用酶联免疫方法(ELISA)测定后计算得到,最终取各组3个复孔的平均值作为最终的TNF-α含量结果;TNF-α抑制率的计算公式如下:
TNF-α抑制率(%)=(1-受试物TNF-α含量平均值/阴性对照TNF-α含量平均值)×100%
分别称取实施例4、对比例5、对比例6制得的眼霜溶于溶剂二甲基亚砜,震摇并充分混匀,制得剂量为2000μg/mL的实施例4受试样品、对比例5受试样品、对比例6受试样品,分别作为功效试验的试验组a、试验组b、试验组c。此外,阴性对照组给与等量含LPS的细胞培养基,阳性对照组给与等量含100μg/mL地塞米松和LPS的细胞培养基。检测得到的TNF-α含量及TNF-α抑制率见表8。
表8对比例和实施例制得眼霜抑制TNF-α分泌作用结果
组别 | TNF-a含量(ng/L) | TNF-α抑制率(%) |
阴性对照组 | 1959.6±56.196 | - |
阳性对照组 | 969.8±42.877** | 50.51% |
试验组a | 1370.0±55.019** | 30.09% |
试验组b | 1671.6±75.479** | 14.70% |
试验组c | 1592.3±60.483** | 18.74% |
(与阴性对照组比较,*P<0.05,**P<0.01)
由表8可知,相较于阴性对照组,阳性对照组及试验组的TNF-α含量均有显著下降且具有极显著差异(P<0.01),但是通过比较TNF-α抑制率可发现,试验组a的抗炎效果显著优于试验组b和试验组c,由此可知,试验组a对应的眼霜针对眼部受损肌肤具有更好的抗炎舒缓功效。
申请人声明,本发明通过上述实施例来说明本发明的具有修护舒缓功效眼霜及其制备方法,但本发明并不局限于上述实施例,即不意味着本发明必须依赖上述实施例才能实施。所属技术领域的技术人员应该明了,对本发明的任何改进,对本发明产品个别原料的等效替换及辅助成分的添加、具体方式的选择等,均落在本发明的保护范围和公开范围之内。
Claims (10)
1.一种含重组胶原蛋白具有修护舒缓功效的组合物,其特征在于,以重量份计,包括以下制备原料:
原料 重量份
重组胶原蛋白 1~10份
透明质酸钠 1~10份
二裂酵母发酵产物溶胞物 1~5份
甘油葡糖苷 1~15份
红没药醇 1~10份
八宝精粹原液 1~15份
松红梅复合精粹 1~15份;
其中,八宝精粹原液包括川芎根提取物、茯苓菌核提取物、白术根提取物、白及根提取物、白蔹根提取物、人工牛黄、珍珠提取物及冰片。
2.根据权利要求1所述的组合物,其特征在于,以重量份计,包括以下制备原料:
原料 重量份
重组胶原蛋白 1~5份
透明质酸钠 1~5份
二裂酵母发酵产物溶胞物 1~3份
甘油葡糖苷 5~10份
红没药醇 5~10份
八宝精粹原液 5~10份
松红梅复合精粹 5~10份。
3.一种眼霜,其特征在于,由权利要求1或2中的组合物以及辅料制备得到。
4.根据权利要求3所述的眼霜,其特征在于,所述辅料选自多元醇、保湿剂、润肤剂、乳化剂、增稠剂、金属离子螯合剂、防腐剂、pH调节剂、抗氧化剂、去离子水中的一种或多种。
5.根据权利要求4所述的眼霜,其特征在于,所述乳化剂为鲸蜡醇棕榈酸酯/山梨坦棕榈酸酯/山梨坦橄榄油酸酯与鲸蜡硬脂醇橄榄油酸酯/山梨坦橄榄油酸酯的复配乳化剂;所述润肤剂选自牛油果树果脂、植物甾醇异硬脂酸酯、氢化聚癸烯、异壬酸异壬酯、聚二甲基硅氧烷、鲸蜡硬脂醇、异十六烷、环五聚二甲基硅氧烷中的一种或多种;所述增稠剂选自季戊四醇二硬脂酸酯、丙烯酸羟乙酯/丙烯酰二甲基牛磺酸钠共聚物、鲸蜡硬脂醇、蜂蜡中的一种或多种。
6.根据权利要求4所述的眼霜,其特征在于,所述金属离子螯合剂选自EDTA二钠、EDTA、EDTA四钠中的一种或多种;所述多元醇选自甘油、丙二醇、丁二醇、山梨醇、双丙甘醇、戊二醇、己二醇中的一种或多种;所述抗氧化剂选自生育酚类、二丁基羟基甲苯、丁基羟基茴香醚、没食子酸酯类中的一种或多种;所述防腐剂选自苯氧乙醇、乙基己基甘油、氯苯甘醚、羟苯甲酯、对羟基苯乙酮、羟苯丙酯、1,2-己二醇、山梨坦辛酸酯中的一种或多种。
7.一种权利要求3-6任一项所述眼霜的制备方法,其特征在于,包括如下步骤:
(1)将第一部分多元醇、金属离子螯合剂、透明质酸钠、去离子水混合后,加热分散均匀,得到混合物1;
(2)将润肤剂、保湿剂、乳化剂、第一部分增稠剂、抗氧化剂、红没药醇、第一部分防腐剂加热搅拌均匀后加入到步骤(1)所得混合物1中,随后均质处理后再搅拌,得到混合物2;
(3)将第二部分增稠剂与第二部分多元醇混合搅拌均匀后加入到步骤(2)所得混合物2中,加热搅拌、均质处理后降温,得混合物3;
(4)将重组胶原蛋白、甘油葡糖苷、八宝精粹原液、松红梅复合精粹、二裂酵母发酵产物溶胞物混匀后加入步骤(3)所得混合物3中,搅拌均匀后降温,得混合物4;
(5)将第二部分防腐剂混匀后加入步骤(4)所得混合物4中,搅拌均匀后进行均质、抽真空处理,然后降温出料,即得所述眼霜。
8.根据权利要求7所述的制备方法,其特征在于,步骤(1)、(2)中加热搅拌温度为75~90℃;步骤(3)中降温至40~50℃;步骤(4)中降温至35~45℃。
9.根据权利要求7所述的制备方法,其特征在于,步骤(2)、(3)中所述均质处理的转速为1000~6000rpm。
10.权利要求1~2任一项所述组合物在制备眼部护理产品中的应用。
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202211058014.XA CN115317429B (zh) | 2022-08-30 | 2022-08-30 | 含重组胶原蛋白具有修护舒缓功效的组合物、含有该组合物的眼霜及制备方法和应用 |
PCT/CN2023/108883 WO2024045952A1 (zh) | 2022-08-30 | 2023-07-24 | 含重组胶原蛋白具有修护舒缓功效的组合物、含有该组合物的眼霜及制备方法和应用 |
US18/538,047 US20240108566A1 (en) | 2022-08-30 | 2023-12-13 | Composition containing recombinant collagen with repairing and soothing effects, eye cream containing the composition and preparation method thereor |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202211058014.XA CN115317429B (zh) | 2022-08-30 | 2022-08-30 | 含重组胶原蛋白具有修护舒缓功效的组合物、含有该组合物的眼霜及制备方法和应用 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN115317429A CN115317429A (zh) | 2022-11-11 |
CN115317429B true CN115317429B (zh) | 2023-05-26 |
Family
ID=83928354
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202211058014.XA Active CN115317429B (zh) | 2022-08-30 | 2022-08-30 | 含重组胶原蛋白具有修护舒缓功效的组合物、含有该组合物的眼霜及制备方法和应用 |
Country Status (3)
Country | Link |
---|---|
US (1) | US20240108566A1 (zh) |
CN (1) | CN115317429B (zh) |
WO (1) | WO2024045952A1 (zh) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN115317429B (zh) * | 2022-08-30 | 2023-05-26 | 马应龙大健康有限公司 | 含重组胶原蛋白具有修护舒缓功效的组合物、含有该组合物的眼霜及制备方法和应用 |
CN116509778A (zh) * | 2023-03-29 | 2023-08-01 | 兰树化妆品股份有限公司 | 扫帚叶澳洲茶叶、发酵姜黄舒缓止痒组合物的制备方法及其测试方法 |
CN117180126A (zh) * | 2023-09-13 | 2023-12-08 | 广州市小谭科技有限公司 | 一种抗敏、舒缓修护蛋白组合物及其应用 |
CN117821358B (zh) * | 2024-01-03 | 2024-06-21 | 广州云丽生物科技有限公司 | 一种松红梅提取物的发酵方法及其应用 |
CN118440181B (zh) * | 2024-04-30 | 2024-11-12 | 西安巨子生物基因技术股份有限公司 | 一种重组人iv型胶原蛋白及其制备方法和用途 |
Citations (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN108618987A (zh) * | 2017-09-21 | 2018-10-09 | 北京幽美生物科技有限公司 | 一种皮肤护理的外用剂及其制备方法 |
CN111700853A (zh) * | 2020-07-22 | 2020-09-25 | 广州澳希亚实业有限公司 | 一种具有抗敏修复功效的化妆品组合物及其应用 |
CN111743797A (zh) * | 2020-07-01 | 2020-10-09 | 广州市爱百伊生物技术有限公司 | 一种具有即时长效祛皱功效的保湿修复组合物及其应用 |
CN112315882A (zh) * | 2020-11-23 | 2021-02-05 | 山东福瑞达生物工程有限公司 | 一种舒缓修护保湿面霜及其制备方法 |
CN112386549A (zh) * | 2020-11-24 | 2021-02-23 | 任秀玲 | 一种用于针对治疗过敏的安肤新肌修护精华 |
CN112704712A (zh) * | 2021-02-23 | 2021-04-27 | 马应龙药业集团股份有限公司 | 一种用于眼部护理的中药组合物及其制备方法和应用 |
CN113413355A (zh) * | 2021-07-08 | 2021-09-21 | 马应龙大健康有限公司 | 一种具有即时提亮淡纹功效的眼霜及其制备方法 |
CN113634011A (zh) * | 2021-08-24 | 2021-11-12 | 伽能生物科技(上海)有限公司 | 松红梅修红精萃组合物的生产集成系统、松红梅修红精萃组合物及其制备方法 |
CN114272184A (zh) * | 2021-05-19 | 2022-04-05 | 广州基米生物科技有限公司 | 一种多肽组合物,包含其的抗衰老修护眼霜及其制备方法 |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2624362C (en) * | 2005-10-03 | 2015-05-26 | Mark A. Pinsky | Liposomes comprising collagen and their use in improved skin care |
AU2012222850B2 (en) * | 2011-02-09 | 2015-06-04 | Forward Scout Enterprises Pty Ltd | Cosmetic or pharmaceutical formulation |
CN110418631A (zh) * | 2017-03-17 | 2019-11-05 | 玫琳凯有限公司 | 化妆品组合物及方法 |
FR3074686B1 (fr) * | 2017-12-12 | 2019-11-15 | Societe D'exploitation De Produits Pour Les Industries Chimiques Seppic | Nouveaux glyceryl polyrhamnosides, procede pour leur preparation et composition cosmetiques et/ou pharmaceutiques en comprenant |
CN109350555A (zh) * | 2018-12-08 | 2019-02-19 | 江苏江山聚源生物技术有限公司 | 一种修复肌肤用重组人源胶原蛋白冻干球及其制备方法 |
CN111529417B (zh) * | 2020-06-08 | 2023-05-30 | 马应龙大健康有限公司 | 一种具有抗蓝光功效修护眼霜及其制备方法 |
CN115317429B (zh) * | 2022-08-30 | 2023-05-26 | 马应龙大健康有限公司 | 含重组胶原蛋白具有修护舒缓功效的组合物、含有该组合物的眼霜及制备方法和应用 |
-
2022
- 2022-08-30 CN CN202211058014.XA patent/CN115317429B/zh active Active
-
2023
- 2023-07-24 WO PCT/CN2023/108883 patent/WO2024045952A1/zh unknown
- 2023-12-13 US US18/538,047 patent/US20240108566A1/en active Pending
Patent Citations (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN108618987A (zh) * | 2017-09-21 | 2018-10-09 | 北京幽美生物科技有限公司 | 一种皮肤护理的外用剂及其制备方法 |
CN111743797A (zh) * | 2020-07-01 | 2020-10-09 | 广州市爱百伊生物技术有限公司 | 一种具有即时长效祛皱功效的保湿修复组合物及其应用 |
CN111700853A (zh) * | 2020-07-22 | 2020-09-25 | 广州澳希亚实业有限公司 | 一种具有抗敏修复功效的化妆品组合物及其应用 |
CN112315882A (zh) * | 2020-11-23 | 2021-02-05 | 山东福瑞达生物工程有限公司 | 一种舒缓修护保湿面霜及其制备方法 |
CN112386549A (zh) * | 2020-11-24 | 2021-02-23 | 任秀玲 | 一种用于针对治疗过敏的安肤新肌修护精华 |
CN112704712A (zh) * | 2021-02-23 | 2021-04-27 | 马应龙药业集团股份有限公司 | 一种用于眼部护理的中药组合物及其制备方法和应用 |
CN114272184A (zh) * | 2021-05-19 | 2022-04-05 | 广州基米生物科技有限公司 | 一种多肽组合物,包含其的抗衰老修护眼霜及其制备方法 |
CN113413355A (zh) * | 2021-07-08 | 2021-09-21 | 马应龙大健康有限公司 | 一种具有即时提亮淡纹功效的眼霜及其制备方法 |
CN113634011A (zh) * | 2021-08-24 | 2021-11-12 | 伽能生物科技(上海)有限公司 | 松红梅修红精萃组合物的生产集成系统、松红梅修红精萃组合物及其制备方法 |
Non-Patent Citations (1)
Title |
---|
Essential oils from New Zealand manuka and kanuka: Chemotaxonomy of Leptospermum;Perry, NB等;《Phytochemistry》;第44卷(第8期);第1485-1494页 * |
Also Published As
Publication number | Publication date |
---|---|
US20240108566A1 (en) | 2024-04-04 |
CN115317429A (zh) | 2022-11-11 |
WO2024045952A1 (zh) | 2024-03-07 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN115317429B (zh) | 含重组胶原蛋白具有修护舒缓功效的组合物、含有该组合物的眼霜及制备方法和应用 | |
CN114099409B (zh) | 一种舒缓修护组合物及其应用 | |
CN106420500B (zh) | 一种含桦褐孔菌提取物的组合物及其应用 | |
CN110051601B (zh) | 一种含矿物泉水的活颜修护组合物 | |
CN109549893B (zh) | 一种具有抗蓝光污染和修复功效的组合物和精华乳及其精华乳的制备方法 | |
CN114376951B (zh) | 一种抗糖化肤用组合物及其应用 | |
CN113925824A (zh) | 一种舒缓修护组合物及其制备方法 | |
CN107929166A (zh) | 一种亲肤按摩油及其制备方法 | |
CN110721148A (zh) | 一种多方位提拉紧致多肽精华液及其制备方法 | |
CN114931534A (zh) | 一种皮肤敏感修护组合物及其应用 | |
CN113876626A (zh) | 一种对蓝光诱导皮肤细胞损伤具有保护作用的组合物及其在化妆品中的应用 | |
CN112353722A (zh) | 一种保湿抗衰修复组合物及其制备方法和应用 | |
CN115054566B (zh) | 一种抗头皮衰老组合物及其制备方法 | |
CN113940896B (zh) | 含维a醇的抗衰肌肤修复液及其制备方法 | |
CN116807947A (zh) | 一种抗衰皮肤调理剂及其应用 | |
CN113384510B (zh) | 一种具有抗光老化、舒缓清凉功效的发酵组合物及其制备方法和应用 | |
CN112791038A (zh) | 一种用于抗敏修复的化妆品组合物及其制备方法 | |
CN112972323A (zh) | 一种大麻叶精华液及其制备方法 | |
CN115282104B (zh) | 一种植物复合提取物、抗敏剂及它们的制备方法和应用 | |
CN111419732A (zh) | 一种防护组合物及其在室内防护化妆品中的应用 | |
CN115969759B (zh) | 光保护植物提取组合物及其应用 | |
CN113456547B (zh) | 一种舒敏抗炎功效的护肤组合物及其应用 | |
CN116869855B (zh) | 含有胶原蛋白的皮肤修护组合物 | |
CN113368164B (zh) | 一种用于抗敏的中药组方发酵物和制备方法及其在化妆品中的应用 | |
CN119257996A (zh) | 一种含鲟鱼子酱提取物的抗皱紧致修护组合物及其应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant |